NEW YORK (GenomeWeb News) — Affymetrix today said that molecular diagnostic shop Ipsogen has signed a Powered by Affymetrix agreement, which gives it non-exclusive access to Affy’s array technology to develop and market in vitro diagnostic tests, initially for breast cancer, worldwide.
 
Financial details of the deal were not disclosed..

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Alnylam's RNAi-based therapy Onpattro, according to Stat News.

Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.

Researchers in the UK are working on using gene drives to control malaria-carrying mosquitoes, the Telegraph reports.

In PLOS this week: genetic architecture mediating gene expression, metabolomic patterns in multiple myeloma, and more.